SK Biopharmaceuticals Co., Ltd.(KR:326030)
â‚©85,900.00-3100.00 (-3.48%)
KR:326030
SK Biopharmaceuticals Co., Ltd. financials statements
â‚©85,900.00
At close:-3100.00 (-3.48%)
Want to see KR:326030 full AI Analyst Report?
SK Biopharmaceuticals Co., Ltd. (326030) Ratios
SK Biopharmaceuticals Co., Ltd. Ratios
KR:326030's free cash flow for Q2 2026 was ₩77.36B. For the 2026 fiscal year, KR:326030's free cash flow was decreased by ₩-790.56M and operating cash flow was ₩78.15B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.31 | 1.64 | 2.02 | 2.99 | 3.18 |
| Quick Ratio | 1.97 | 1.36 | 1.60 | 2.43 | 2.83 |
| Cash Ratio | 1.04 | 0.81 | 0.99 | 0.64 | 1.52 |
| Solvency Ratio | 0.76 | 0.56 | -0.04 | -0.36 | 0.38 |
| Operating Cash Flow Ratio | 0.61 | 0.24 | -0.39 | -0.98 | -0.63 |
| Short-Term Operating Cash Flow Coverage | 21.42 | 0.63 | -1.88 | 0.00 | 0.00 |
| Net Current Asset Value | â‚© 311.19B | â‚© 188.54B | â‚© 86.50B | â‚© 140.24B | â‚© 271.75B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.18 | 0.25 | 0.23 | 0.02 |
| Debt-to-Equity Ratio | 0.06 | 0.34 | 0.63 | 0.49 | 0.04 |
| Debt-to-Capital Ratio | 0.06 | 0.25 | 0.39 | 0.33 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.25 | 0.31 | 0.00 |
| Financial Leverage Ratio | 1.47 | 1.90 | 2.55 | 2.10 | 1.45 |
| Debt Service Coverage Ratio | 20.05 | 1.58 | -0.00 | -33.02 | 170.27 |
| Interest Coverage Ratio | 26.52 | 9.02 | -2.49 | -35.27 | 100.27 |
| Debt to Market Cap | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 |
| Interest Debt Per Share | 722.88 | 2492.11 | 2379.29 | 2038.14 | 213.05 |
| Net Debt to EBITDA | -1.17 | -1.37 | 7.07 | -0.41 | -1.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 92.21% | 92.13% | 90.40% | 84.66% | 94.66% |
| EBIT Margin | 28.86% | 15.21% | -6.77% | -56.36% | 37.27% |
| EBITDA Margin | 31.25% | 18.39% | -2.46% | -51.09% | 40.05% |
| Operating Profit Margin | 28.86% | 17.59% | -5.81% | -53.24% | 22.68% |
| Pretax Profit Margin | 21.35% | 13.26% | -12.36% | -57.87% | 17.03% |
| Net Profit Margin | 37.77% | 43.96% | -9.27% | -56.64% | 15.49% |
| Continuous Operations Profit Margin | 35.83% | 41.45% | -9.97% | -56.64% | 15.49% |
| Net Income Per EBT | 176.92% | 331.61% | 74.98% | 97.87% | 90.98% |
| EBT Per EBIT | 73.99% | 75.35% | 212.59% | 108.69% | 75.06% |
| Return on Assets (ROA) | 22.28% | 23.22% | -4.55% | -20.99% | 10.07% |
| Return on Equity (ROE) | 32.83% | 44.07% | -11.59% | -44.05% | 14.60% |
| Return on Capital Employed (ROCE) | 22.58% | 15.04% | -4.28% | -26.15% | 19.17% |
| Return on Invested Capital (ROIC) | 22.17% | 12.07% | -3.09% | -25.31% | 17.25% |
| Return on Tangible Assets | 23.27% | 23.97% | -4.66% | -21.55% | 10.38% |
| Earnings Yield | 2.74% | 2.77% | -0.41% | -2.49% | 0.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.92 | 3.11 | 3.06 | 3.67 | 7.49 |
| Payables Turnover | 5.90 | 12.66 | 14.53 | 1.63 | 1.32 |
| Inventory Turnover | 0.55 | 0.39 | 0.33 | 0.42 | 0.43 |
| Fixed Asset Turnover | 11.68 | 12.46 | 7.43 | 12.10 | 18.25 |
| Asset Turnover | 0.59 | 0.53 | 0.49 | 0.37 | 0.65 |
| Working Capital Turnover Ratio | 2.20 | 2.18 | 1.24 | 0.76 | 1.22 |
| Cash Conversion Cycle | 727.56 | 1034.40 | 1192.00 | 754.74 | 620.70 |
| Days of Sales Outstanding | 125.06 | 117.46 | 119.15 | 99.37 | 48.72 |
| Days of Inventory Outstanding | 664.38 | 945.76 | 1097.98 | 878.67 | 848.66 |
| Days of Payables Outstanding | 61.88 | 28.82 | 25.12 | 223.30 | 276.68 |
| Operating Cycle | 789.45 | 1063.22 | 1217.12 | 978.04 | 897.38 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2305.29 | 1211.80 | -1202.88 | -2042.06 | -1185.90 |
| Free Cash Flow Per Share | 2217.29 | 1040.38 | -1244.37 | -2118.18 | -1262.42 |
| Dividend Paid and CapEx Coverage Ratio | 26.20 | 7.07 | -28.99 | -26.83 | -15.50 |
| Capital Expenditure Coverage Ratio | 26.20 | 7.07 | -28.99 | -26.83 | -15.50 |
| Operating Cash Flow Coverage Ratio | 3.69 | 0.51 | -0.53 | -1.03 | -5.90 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.17 | -0.27 | -0.65 | -0.22 |
| Free Cash Flow Yield | 1.78% | 0.94% | -1.21% | -2.97% | -1.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 36.55 | 36.22 | -245.54 | -40.10 | 117.39 |
| Price-to-Sales (P/S) Ratio | 13.81 | 15.89 | 22.75 | 22.71 | 18.18 |
| Price-to-Book (P/B) Ratio | 12.00 | 15.93 | 28.46 | 17.66 | 17.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 56.19 | 106.79 | -82.85 | -33.71 | -77.00 |
| Price-to-Operating Cash Flow Ratio | 54.05 | 91.68 | -85.71 | -34.96 | -81.96 |
| Price-to-Earnings Growth (PEG) Ratio | 3.28 | -0.04 | 3.21 | 0.13 | -0.95 |
| Enterprise Value Multiple | 43.00 | 85.02 | -918.22 | -44.87 | 44.14 |
| Enterprise Value | 9.50T | 8.56T | 8.01T | 5.64T | 7.40T |
| EV to EBITDA | 43.00 | 85.02 | -918.22 | -44.87 | 44.14 |
| EV to Sales | 13.44 | 15.64 | 22.58 | 22.92 | 17.68 |
| EV to Free Cash Flow | 54.70 | 105.09 | -82.22 | -34.02 | -74.87 |
| EV to Operating Cash Flow | 52.62 | 90.22 | -85.06 | -35.29 | -79.70 |
| Tangible Book Value Per Share | 9896.89 | 6913.99 | 3869.30 | 3822.86 | 5430.62 |
| Shareholders’ Equity Per Share | 10381.87 | 6975.51 | 3622.47 | 4042.25 | 5671.95 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.68 | -2.13 | 0.19 | 0.02 | 0.09 |
| Revenue Per Share | 9024.57 | 6992.41 | 4531.71 | 3143.53 | 5345.79 |
| Net Income Per Share | 3408.76 | 3074.05 | -419.89 | -1780.43 | 828.03 |
| Tax Burden | 1.77 | 3.32 | 0.75 | 0.98 | 0.91 |
| Interest Burden | 0.74 | 0.87 | 1.82 | 1.03 | 0.46 |
| Research & Development to Revenue | 0.25 | 0.29 | 0.39 | 0.50 | 0.27 |
| SG&A to Revenue | 0.21 | 0.21 | 0.58 | 0.46 | 0.21 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.68 | 0.42 | 2.86 | 1.15 | -1.43 |
Currency in KRW

